Symbols / PRTA
PRTA Chart
About
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 469.40M |
| Enterprise Value | 183.43M | Income | -244.09M | Sales | 9.68M |
| Book/sh | 5.21 | Cash/sh | 5.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -8.72 | PEG | — |
| P/S | 48.47 | P/B | 1.67 | P/C | — |
| EV/EBITDA | -1.00 | EV/Sales | 18.94 | Quick Ratio | 7.53 |
| Current Ratio | 7.72 | Debt/Eq | 2.98 | LT Debt/Eq | — |
| EPS (ttm) | -5.20 | EPS next Y | -1.00 | EPS Growth | — |
| Revenue Growth | -99.00% | Earnings | 2026-05-07 | ROA | -26.40% |
| ROE | -63.62% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -1295.76% | Profit Margin | 0.00% | Shs Outstand | 53.83M |
| Shs Float | 39.69M | Short Float | 15.66% | Short Ratio | 14.08 |
| Short Interest | — | 52W High | 16.16 | 52W Low | 4.32 |
| Beta | -0.25 | Avg Volume | 583.07K | Volume | 84.60K |
| Target Price | $20.50 | Recom | Buy | Prev Close | $8.97 |
| Price | $8.72 | Change | -2.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.50
Mean price target
2. Current target
$8.72
Latest analyst target
3. DCF / Fair value
$20.50
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$8.72
Low
$8.00
High
$36.00
Mean
$20.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | main | RBC Capital | Sector Perform → Sector Perform | $12 |
| 2025-12-01 | main | Citizens | Market Outperform → Market Outperform | $19 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-11-07 | main | RBC Capital | Sector Perform → Sector Perform | $11 |
| 2025-10-28 | main | Piper Sandler | Overweight → Overweight | $36 |
| 2025-10-07 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-09-02 | main | JMP Securities | Market Outperform → Market Outperform | $11 |
| 2025-08-28 | main | Piper Sandler | Overweight → Overweight | $15 |
| 2025-08-28 | main | Chardan Capital | Buy → Buy | $18 |
| 2025-08-05 | main | RBC Capital | Sector Perform → Sector Perform | $10 |
| 2025-08-05 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-08-05 | main | Chardan Capital | Buy → Buy | $18 |
| 2025-06-20 | reit | Cantor Fitzgerald | Neutral → Neutral | — |
| 2025-05-28 | down | B of A Securities | Neutral → Underperform | $4 |
| 2025-05-27 | down | Oppenheimer | Outperform → Perform | — |
| 2025-05-27 | main | Piper Sandler | Overweight → Overweight | $81 |
| 2025-05-27 | main | JMP Securities | Market Outperform → Market Outperform | $29 |
| 2025-05-27 | main | Chardan Capital | Buy → Buy | $18 |
| 2025-05-27 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $30 |
- FTRE vs. PRTA: Which Stock Is the Better Value Option? - Yahoo Finance Fri, 13 Feb 2026 08
- RBC Capital Raises Price Target for Prothena Corp (PRTA) to $12. - GuruFocus Fri, 20 Feb 2026 17
- Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights - Business Wire hu, 19 Feb 2026 21
- Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus - Finviz Fri, 20 Feb 2026 17
- (PRTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Sun, 15 Feb 2026 19
- Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? - Zacks Investment Research Mon, 16 Feb 2026 08
- Prothena (NASDAQ: PRTA) director Paula Cobb departs board, leaving 8 members - Stock Titan Fri, 12 Dec 2025 08
- Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance hu, 19 Feb 2026 22
- Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus - Nasdaq Fri, 07 Nov 2025 08
- Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire hu, 12 Feb 2026 08
- Major Alzheimer's Breakthrough: BMS-Prothena Drug Gets FDA Fast Track for Targeting Tau Protein - Stock Titan Wed, 01 Oct 2025 07
- How (PRTA) Movements Inform Risk Allocation Models - Stock Traders Daily Wed, 04 Feb 2026 18
- PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? - Nasdaq Fri, 04 Jul 2025 07
- Prothena Corporation plc (PRTA): A Bull Case Theory - Yahoo Finance Wed, 22 Oct 2025 07
- Prothena Down 40% Year to Date: What Lies Ahead for the Stock? - Yahoo Finance hu, 11 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | WALKER KARIN LORRAINE | Officer | — | 2025-07-28 00:00:00 | D |
| 1 | 95000 | — | — | Stock Award(Grant) at price 0.00 per share. | NGUYEN TRAN BRYAN | Chief Financial Officer | — | 2025-07-28 00:00:00 | D |
| 2 | 140000 | — | — | Stock Award(Grant) at price 0.00 per share. | KINNEY GENE G PH.D. | Chief Executive Officer | — | 2025-07-28 00:00:00 | D |
| 3 | 85000 | — | — | Stock Award(Grant) at price 0.00 per share. | ZAGO WAGNER M | Officer | — | 2025-07-28 00:00:00 | D |
| 4 | 80000 | — | — | Stock Award(Grant) at price 0.00 per share. | MALECEK MICHAEL J. | Officer | — | 2025-07-28 00:00:00 | D |
| 5 | 130000 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITH BRANDON S | Chief Operating Officer | — | 2025-07-28 00:00:00 | D |
| 6 | 85000 | — | — | Stock Award(Grant) at price 0.00 per share. | SWANSON CHAD PH.D. | Officer | — | 2025-07-28 00:00:00 | D |
| 7 | 6279684 | 50839807 | — | Sale at price 7.64 - 8.36 per share. | ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-06 00:00:00 | I |
| 8 | 747700 | — | — | Stock Gift at price 0.00 per share. | SCULLY WILLIAM P | Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-15 00:00:00 | D/I |
| 9 | 207436 | 2749916 | — | Purchase at price 12.79 - 15.91 per share. | SCULLY WILLIAM P | Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -9.50K | -38.39K | -27.36K | 0.00 |
| TaxRateForCalcs | 0.05 | 0.08 | 0.07 | 0.07 |
| NormalizedEBITDA | -153.48M | -189.65M | -130.42M | 73.09M |
| TotalUnusualItems | -185.00K | -458.00K | -397.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -185.00K | -458.00K | -397.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -122.31M | -147.03M | -116.95M | 66.97M |
| ReconciledDepreciation | 893.00K | 928.00K | 744.00K | 1.11M |
| EBITDA | -153.67M | -190.11M | -130.81M | 73.09M |
| EBIT | -154.56M | -191.04M | -131.56M | 71.97M |
| NetInterestIncome | 25.82M | 31.01M | 6.35M | 42.00K |
| InterestIncome | 25.82M | 31.01M | 6.35M | 42.00K |
| NormalizedIncome | -122.13M | -146.61M | -116.58M | 66.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -122.31M | -147.03M | -116.95M | 66.97M |
| TotalExpenses | 289.72M | 282.41M | 185.46M | 128.60M |
| TotalOperatingIncomeAsReported | -154.56M | -191.04M | -131.56M | 71.97M |
| DilutedAverageShares | 53.77M | 53.22M | 47.37M | 48.46M |
| BasicAverageShares | 53.77M | 53.22M | 47.37M | 44.23M |
| DilutedEPS | -2.27 | -2.76 | -2.47 | 1.38 |
| BasicEPS | -2.27 | -2.76 | -2.47 | 1.51 |
| DilutedNIAvailtoComStockholders | -122.31M | -147.03M | -116.95M | 66.97M |
| NetIncomeCommonStockholders | -122.31M | -147.03M | -116.95M | 66.97M |
| NetIncome | -122.31M | -147.03M | -116.95M | 66.97M |
| NetIncomeIncludingNoncontrollingInterests | -122.31M | -147.03M | -116.95M | 66.97M |
| NetIncomeContinuousOperations | -122.31M | -147.03M | -116.95M | 66.97M |
| TaxProvision | -6.62M | -13.45M | -8.66M | 4.95M |
| PretaxIncome | -128.93M | -160.48M | -125.61M | 71.92M |
| OtherIncomeExpense | -185.00K | -458.00K | -397.00K | -96.00K |
| OtherNonOperatingIncomeExpenses | -458.00K | -397.00K | -96.00K | |
| SpecialIncomeCharges | 0.00 | |||
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | -185.00K | -458.00K | -397.00K | |
| NetNonOperatingInterestIncomeExpense | 25.82M | 31.01M | 6.35M | 42.00K |
| InterestIncomeNonOperating | 25.82M | 31.01M | 6.35M | 42.00K |
| OperatingIncome | -154.56M | -191.04M | -131.56M | 71.97M |
| OperatingExpense | 289.72M | 282.41M | 185.46M | 128.60M |
| ResearchAndDevelopment | 222.52M | 220.57M | 135.56M | 82.28M |
| SellingGeneralAndAdministration | 67.20M | 61.84M | 49.90M | 46.32M |
| GeneralAndAdministrativeExpense | 67.20M | 61.84M | 49.90M | 46.32M |
| OtherGandA | 67.20M | 61.84M | 49.90M | 46.32M |
| TotalRevenue | 135.16M | 91.37M | 53.91M | 200.58M |
| OperatingRevenue | 135.16M | 91.37M | 53.91M | 200.58M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 53.83M | 53.68M | 52.10M | 46.66M |
| ShareIssued | 53.83M | 53.68M | 52.10M | 46.66M |
| TotalDebt | 10.84M | 11.84M | 6.47M | 12.33M |
| TangibleBookValue | 486.93M | 561.37M | 622.04M | 466.04M |
| InvestedCapital | 486.93M | 561.37M | 622.04M | 466.04M |
| WorkingCapital | 436.91M | 582.39M | 668.95M | 551.36M |
| NetTangibleAssets | 486.93M | 561.37M | 622.04M | 466.04M |
| CapitalLeaseObligations | 10.84M | 11.84M | 6.47M | 12.33M |
| CommonStockEquity | 486.93M | 561.37M | 622.04M | 466.04M |
| TotalCapitalization | 486.93M | 561.37M | 622.04M | 466.04M |
| TotalEquityGrossMinorityInterest | 486.93M | 561.37M | 622.04M | 466.04M |
| StockholdersEquity | 486.93M | 561.37M | 622.04M | 466.04M |
| RetainedEarnings | -1.10B | -980.03M | -833.00M | -716.05M |
| AdditionalPaidInCapital | 1.59B | 1.54B | 1.45B | 1.18B |
| CapitalStock | 538.00K | 537.00K | 521.00K | 466.00K |
| CommonStock | 538.00K | 537.00K | 521.00K | 466.00K |
| TotalLiabilitiesNetMinorityInterest | 60.18M | 135.02M | 135.99M | 143.32M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 11.68M | 78.13M | 85.85M | 109.87M |
| OtherNonCurrentLiabilities | 553.00K | 553.00K | ||
| NonCurrentDeferredLiabilities | 3.45M | 67.41M | 85.29M | 102.93M |
| NonCurrentDeferredRevenue | 3.45M | 67.41M | 85.29M | 102.93M |
| LongTermDebtAndCapitalLeaseObligation | 8.23M | 10.72M | 0.00 | 6.39M |
| LongTermCapitalLeaseObligation | 8.23M | 10.72M | 0.00 | 6.39M |
| CurrentLiabilities | 48.50M | 56.89M | 50.15M | 33.45M |
| OtherCurrentLiabilities | 1.38M | 2.42M | 503.00K | 405.00K |
| CurrentDeferredLiabilities | 8.85M | 0.00 | 11.44M | 7.66M |
| CurrentDeferredRevenue | 8.85M | 0.00 | 11.44M | 7.66M |
| CurrentDebtAndCapitalLeaseObligation | 2.61M | 1.11M | 6.47M | 5.94M |
| CurrentCapitalLeaseObligation | 2.61M | 1.11M | 6.47M | 5.94M |
| PayablesAndAccruedExpenses | 35.67M | 53.36M | 31.73M | 19.45M |
| CurrentAccruedExpenses | 27.90M | 27.97M | 22.46M | 15.76M |
| Payables | 7.77M | 25.39M | 9.27M | 3.69M |
| TotalTaxPayable | 0.00 | |||
| IncomeTaxPayable | 0.00 | |||
| AccountsPayable | 7.77M | 25.39M | 9.27M | 3.69M |
| TotalAssets | 547.11M | 696.38M | 758.03M | 609.37M |
| TotalNonCurrentAssets | 61.70M | 57.10M | 38.94M | 24.56M |
| OtherNonCurrentAssets | 4.67M | 7.21M | 12.72M | 3.35M |
| NonCurrentDeferredAssets | 43.24M | 33.89M | 18.20M | 7.07M |
| NonCurrentDeferredTaxesAssets | 43.24M | 33.89M | 18.20M | 7.07M |
| NetPPE | 13.79M | 16.00M | 8.01M | 14.13M |
| AccumulatedDepreciation | -8.31M | -7.42M | -11.17M | -10.46M |
| GrossPPE | 22.10M | 23.41M | 19.18M | 24.60M |
| Leases | 0.00 | 1.50M | 1.39M | |
| OtherProperties | 10.71M | 12.16M | 6.28M | 12.12M |
| MachineryFurnitureEquipment | 11.39M | 11.25M | 11.40M | 11.08M |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 485.41M | 639.28M | 719.10M | 584.81M |
| OtherCurrentAssets | 1.17M | 2.14M | 1.71M | 766.00K |
| RestrictedCash | 0.00 | 1.35M | 0.00 | 0.00 |
| PrepaidAssets | 12.86M | 11.80M | 6.92M | 4.94M |
| Receivables | 0.00 | 5.16M | 62.00K | 13.00K |
| OtherReceivables | 62.00K | 13.00K | ||
| AccountsReceivable | 0.00 | 5.16M | 0.00 | 13.00K |
| CashCashEquivalentsAndShortTermInvestments | 471.39M | 618.83M | 710.41M | 579.09M |
| CashAndCashEquivalents | 471.39M | 618.83M | 710.41M | 579.09M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -150.35M | -136.72M | -109.28M | 92.03M |
| RepurchaseOfCapitalStock | -353.00K | |||
| IssuanceOfCapitalStock | 0.00 | 23.58M | 223.62M | 174.79M |
| CapitalExpenditure | -298.00K | -2.81M | -464.00K | -575.00K |
| IncomeTaxPaidSupplementalData | 3.17M | 1.55M | 2.66M | 580.00K |
| EndCashPosition | 472.25M | 621.04M | 712.62M | 580.45M |
| BeginningCashPosition | 621.04M | 712.62M | 580.45M | 298.08M |
| ChangesInCash | -148.79M | -91.58M | 132.17M | 282.36M |
| FinancingCashFlow | 1.55M | 45.10M | 241.46M | 190.33M |
| CashFlowFromContinuingFinancingActivities | 1.55M | 45.10M | 241.46M | 190.33M |
| ProceedsFromStockOptionExercised | 1.91M | 21.52M | 17.84M | 15.54M |
| NetCommonStockIssuance | -353.00K | 23.58M | 223.62M | 174.79M |
| CommonStockPayments | -353.00K | |||
| CommonStockIssuance | 0.00 | 23.58M | 223.62M | 174.79M |
| InvestingCashFlow | -298.00K | -2.77M | -464.00K | -575.00K |
| CashFlowFromContinuingInvestingActivities | -298.00K | -2.77M | -464.00K | -575.00K |
| NetPPEPurchaseAndSale | -298.00K | -2.77M | -464.00K | -575.00K |
| SaleOfPPE | 0.00 | 37.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -298.00K | -2.81M | -464.00K | -575.00K |
| OperatingCashFlow | -150.05M | -133.91M | -108.82M | 92.61M |
| CashFlowFromContinuingOperatingActivities | -150.05M | -133.91M | -108.82M | 92.61M |
| ChangeInWorkingCapital | -67.94M | -20.53M | -18.80M | -10.40M |
| ChangeInOtherWorkingCapital | -55.11M | -29.33M | -13.86M | 348.00K |
| ChangeInOtherCurrentLiabilities | -2.24M | -6.36M | -6.00M | -5.51M |
| ChangeInPayablesAndAccruedExpense | -18.30M | 22.86M | 11.87M | -492.00K |
| ChangeInPayable | -18.30M | 22.86M | 11.87M | -492.00K |
| ChangeInAccountPayable | -18.30M | 22.86M | 11.87M | -492.00K |
| ChangeInPrepaidAssets | 2.54M | -2.54M | -10.81M | -4.76M |
| ChangeInReceivables | 5.16M | -5.16M | 0.00 | 15.00K |
| ChangesInAccountReceivables | 5.16M | -5.16M | 0.00 | 15.00K |
| OtherNonCashItems | 2.69M | 7.48M | 6.00M | 5.69M |
| StockBasedCompensation | 45.96M | 40.91M | 31.32M | 24.66M |
| DeferredTax | -9.35M | -15.69M | -11.13M | 4.57M |
| DeferredIncomeTax | -9.35M | -15.69M | -11.13M | 4.57M |
| DepreciationAmortizationDepletion | 893.00K | 928.00K | 744.00K | 1.11M |
| DepreciationAndAmortization | 893.00K | 928.00K | 744.00K | 1.11M |
| Depreciation | 6.80M | |||
| OperatingGainsLosses | 15.00K | 1.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 15.00K | 1.00K | 0.00 |
| NetIncomeFromContinuingOperations | -122.31M | -147.03M | -116.95M | 66.97M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PRTA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|